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Approximately 1 in 8 women will be diagnosed with breast cancer during their lifetime; 
however, continuing advances in the field of medicine have increased the expected survival rate.  
With such an increase in survival among breast cancer patients, there has been an emphasis on 
quality of life post-surgery.  One of the most feared complications following breast cancer 
surgery is the development of lymphedema.  Approximately 20-30% of women treated for breast 
cancer are affected by the onset of secondary lymphedema.  Unfortunately, there is no cure and 
only a portion of women witness improvements in arm symptoms from the available treatments. 
Currently, there is no accepted model to successfully predict which women are at higher 
risk for development of lymphedema post treatment.  An individual’s genotype as a risk factor is 
not typically considered when studying patient specific risk information.  S ince treatment for 
lymphedema is most successful when initiated early, identification of high risk women through 
detection of genetic risk factors can aid in early diagnosis, improved treatment outcome, and 
even prevention which is significant to the field of public health.   
Mutations in the HGF and MET genes had been previously identified in patients who 
developed lymphedema secondary to breast cancer treatment suggesting the possibility of a 
genetic predisposition to development of lymphedema.  More recently, findings of mutations in 
the connexin 47 ( GJA12/GJC2) gene in breast cancer patients diagnosed with secondary 
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lymphedema confirmed a genetic predisposition.  T here are several connexins expressed in 
lymphatics and further investigation of their involvement with lymphedema is warranted.    
The purpose of this study is to continue the investigation of the connexin genes and their 
involvement in secondary lymphedema.  This is a case-control study designed to sequence the 
connexin 40 gene in women treated for breast cancer with and without a diagnosis of secondary 
lymphedema.  In this study, 91 cases and 168 controls were sequenced for the connexin 40 gene.  
No previously unidentified connexin 40 mutations were found in this cohort of women analyzed.  
Despite no mutations being identified in connexin 40, further studies of the connexin genes are 
warranted given their expression and involvement in the lymphatic system. 
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1.0  INTRODUCTION 
1.1 ANATOMY AND PATHOPHYSIOLOGY OF LYMPHEDEMA 
The lymphatic vascular system has been described as a mass transport system[1] responsible for 
the drainage and return of lymph fluid to the intravascular circulatory system.  Fluid of the 
lymphatic systems contains water, proteins, lipids, foreign matter, cellular debris and a variety of 
cells[2].  Approximately 90% of interstitial fluid enters the venous capillaries and returns to 
circulation[3].  The other 10% of interstitial fluid, lymph fluid, contains macromolecules which 
are too large to pass through the venous capillaries.  Therefore, this fluid enters the lymphatic 
capillaries and is filtered by the lymph nodes before returning to venous circulation.  There are 
three main physiological functions of the lymphatic system which include maintenance and 
homeostasis of interstitial fluid, uptake of dietary lipids, and progression of the immune cell 
response[4].   
The lymphatic vascular system consists of a network of branched capillaries and ducts[4] 
in which two main types of lymphatic vessels exist: the smaller initial lymphatic vessel and the 
collecting lymphatic vessel.  The smaller initial lymphatic vessel includes the smallest lymphatic 
capillary and the larger precollector vessel.  The one-way, open-ended small lymphatic 
capillaries are where interstitial fluid is initially drained from tissue.  The small lymphatic 
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capillaries funnel into precollector vessels which drain into the collecting lymphatic vessels[5].  
The collecting lymphatic vessels are composed of lymphangion units separated by intraluminal 
one-way valves.  These valves open in response to positive pressure or upstream flow of fluid 
while reverse flow closes the valves.  Collecting lymphatic vessels are covered by a continuous 
basement membrane and smooth muscle cells.  Endothelial cells present in these vessels have an 
overlapping elongated shape thereby forming continuous junctions preventing any leakages 
during lymph transport[4].  The structure and mechanism of collecting lymphatic vessels allow 
for coordinated opening and closing of the valves resulting in efficient unidirectional flow of 
lymph transport.   
Collecting lymphatic vessels are the major limb lymphatic vessels which provide flow to 
the lymph nodes[5].  Movement of interstitial fluid is dependent upon inherent forces of pressure 
as the basic motor function for the lymphatic system.  Changes in capillary hydrostatic pressure 
and tissue oncotic pressure drive filtration while interstitial hydrostatic pressure and plasma 
oncotic pressure promote absorption[1].  Movement of tissues in response to pressure and 
contraction of smooth muscle cells in the collecting vessels result in compression and expansion 
of the lymphatics.  Compression and expansion of the lymphatics regulate lymph flow through 
the lymphatic system[1, 5].   
Lymphedema occurs in response to failure of the lymphatic system.  It is caused by a 
decrease in lymph circulation as the result of an imbalance between the rates of interstitial fluid 
production and removal.  Lymphedema is thus characterized by chronic accumulation of protein-
rich fluid within the interstitial space[1, 6, 7].  Lymphedema is typically a consequence of either 
increased lymphatic flow or an intrinsic reduction in transport capacity.  Lymphatic flow may be 
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increased by the presence of deep vein thrombosis, heart failure, malnutrition hypoproteinemia, 
cirrhosis, nephritic syndrome, or local inflammatory responses.  Such conditions lead to a net 
increase in capillary pressure serving as a driving force for lymph fluid production[1, 6].  On the 
other hand, intrinsic reduction in transport capacity may be caused by a vascular disruption or 
malformation.  There are multiple causes that may be responsible for impaired transport 
including trauma, infections, tumor invasion, external sources of compression, and heritable 
disorders affecting lymphatic pathogenesis[6].  The exact etiology of lymphedema is unknown in 
the majority of cases.  Despite the various potential causes the implication is the same: entry of 
fluid exceeds the capacity of the lymphatics to remove the fluid resulting in disease.   
1.2 CLASSIFICATION OF LYMPHEDEMA 
Lymphedema is estimated to affect approximately 2-3 million individuals in the United 
States[8].  It is a chronic and progressive disease which is often debilitating for many affected 
individuals.   Lymphedema can be classified into two main categories: primary and secondary.   
1.2.1 Primary Lymphedema 
Primary lymphedema is characterized by an inborn error of lymphatic development or 
function[6].  P rimary lymphedema can be further classified and is most commonly grouped 
based upon age of onset into three subcategories: congenital lymphedema, lymphedema praecox, 
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and lymphedema tarda[5].  Congenital lymphedema presents at birth or within the first two years 
of life.  Congenital lymphedema more commonly presents as a bilateral manifestation with both 
right and left lower extremities being affected.  Lymphedema praecox commonly appears around 
puberty; however, it can occur any time up to the third decade of life.  The majority of 
lymphedema cases are lymphedema praecox.  L ymphedema praecox, unlike congenital 
lymphedema, typically exists as a unilateral presentation affecting an individual’s foot and 
calf[5, 7].   Lymphedema tarda is recognized as onset after the age of 35.  It is the rarest of the 
primary lymphedema forms accounting for less than 10% of reported cases[7].  Additionally, 
there are particular forms of inherited primary lymphedema which occur less commonly.  There 
are several recognized inherited lymphedema syndromes with identified gene mutations.  T he 
genetic basis in many of these syndromes continues to be investigated. 
1.2.2 Secondary Lymphedema 
In addition to primary lymphedema, lymphedema that is acquired is referred to as secondary 
lymphedema.  It is the most common form of lymphedema with an incidence of greater than 100 
million worldwide[2].  Secondary lymphedema is the result of disruption to the lymphatic system 
caused by an external event.  S urgery, tumor formation, trauma, radiation therapy, and filarial 
infection are just a few examples of events which can result in lymphatic obstruction and 
subsequential fluid accumulation[6, 8].  Filarial infection is the most common cause of 
secondary lymphedema worldwide. 
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1.2.2.1 Secondary Lymphedema Related to Breast Cancer 
Breast cancer is the most common malignancy occurring in women in the United States[2].  
Approximately 1 in every 8 women are diagnosed with breast cancer during their lifetime[9].  In 
2011, it was estimated that 288,130 w omen received a diagnosis of breast cancer of which 
39,520 women will die from the disease[10].  Advances in breast cancer treatment over the years 
have improved the long term survival of many women by use of surgery, radiation, 
chemotherapy, and hormone therapy.  However, development of secondary lymphedema remains 
a common complication following cancer treatment.   
In treating breast cancer, lymph node status serves as a significant marker in determining 
the best methods of treatment[2].  Axillary lymph node dissection (ALND) involves removal of 
the axillary lymph nodes and such surgical excision can obstruct the lymphatic system.  Studies 
have shown a correlation between the extent of lymph nodes removed and the severity of 
lymphedema[8].  Incidence of lymphedema following ALND can be as a high as 45%-56%[2, 
11].  Newer techniques such as sentinel node (SLND) biopsy involve excision of the first lymph 
node(s) to receive drainage from the breast.  T he risk of lymphedema after SLND is lower 
compared to that of ALND with estimates of lymphedema incidence being approximately 7%-
15%[12, 13].  Differences in surgical procedures also affect risk estimates as secondary 
lymphedema is more prevalent in women treated with mastectomy compared to breast-
conserving surgery techniques.  Approximately 20% of women treated with mastectomy will 
develop lymphedema compared to 8% of women who received breast-conserving surgery[14].  
Risk of lymphedema may also be increased by adjuvant radiation therapy typically received by 
patients following lumpectomy or mastectomy procedures.  Theories propose secondary 
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lymphedema induced via radiation exposure is related to fibrosis of the lymph nodes resulting in 
constraint of lymphatic channels[15].  H owever, the exact etiology of radiation induced 
lymphedema is unknown.  Even with improvements in surgical techniques and treatment options, 
lymphedema remains a common debilitating complication post treatment[16, 17]. 
Secondary lymphedema effects on average approximately 20-30% of patients treated for 
breast cancer[18-20] with onset occurring anywhere from weeks to years after treatment[21].  
The estimates of lymphedema vary due to the lack of a universal diagnostic definition and the 
application of a variety of measurement techniques.  One study examining a cohort of 287 
women found nearly one in two patients report at least moderate to extreme upper body 
symptoms at 6 years following a breast cancer diagnosis[19].  Development of secondary 
lymphedema can cause a significant impact on the quality of life for such individuals[3].  Not 
only does lymphedema cause physical impairment and dysfunction but it also may result in 
altered body image, anxiety, and depression.  The psychological distress caused by this disease 
can ultimately affect social relationships as well as lower self-esteem.  Findings in a study by 
Hayes et. al. (2011) suggest that lymphedema may also have an influence on survival following 
breast cancer treatment.   
1.3 EVALUATION AND DIAGNOSIS 
The majority of lymphedema diagnoses are made by clinical observation through physical 
examination[1].  Lymphedema can be classified as mild (Grade I), moderate (Grade II), or severe 
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(Grade III)[21].  Grade I pitting occurs in response to pressure and edema improves with 
elevation of the limb.  With grade II classification the affected limb does not pit with application 
of pressure and the edema continues to worsen.  Grade III is characterized by continuous 
swelling and associated skin changes such as a thick appearance with the presence of folds.   
When the diagnosis of lymphedema is not clearly distinguished by physical exam, there 
are a variety of measurement evaluations which can establish a diagnosis.  The most sensitive 
marker involves finding at least a 200 ml difference in arm volume by water displacement 
volumetry[22].  However, breast cancer related lymphedema does not typically present with 
uniform edema throughout the entire length of the arm and there is evidence that segmental 
differences in drainage may result in segmental presentation of swelling[23, 24].  In this case, 
diagnosis based on a total volume difference may not be as sensitive.  More commonly used is 
circumferential measurement criteria including at least a 2 cm difference in arm circumference 
between any two points when the measurements are made every 4 cm along the axis[2, 15, 22].  
Women treated for breast cancer who self-report symptoms of heaviness are reported to correlate 
with this 2 cm or greater difference in limb circumference[25].  However, limitations exist with 
circumferential measurement use such as difficulty with control of intrarater and interrater 
reliability[21, 26].  Approximately 12% of individuals are given a false diagnosis based on 
circumferential measurement alone[27]. 
An alternative method measures the volume of fluid in each limb and the entire body 
through use of bioimpedance spectroscopy (BIS) technology[28].  BIS uses electrodes attached 
to the skin of the hands and feet which send a small electric current throughout each limb and the 
entire body.  The resistance of flow in response to this electric current is measured at multiple 
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frequencies.  By measuring a range of frequencies, BIS derives the resistance or impedance to 
flow at a frequency comparable to the impedance of extracellular fluid (0 HZ).  BIS is one of the 
few techniques analyzing body composition and distinguishing extracellular fluid from total limb 
volume.  In turn, BIS does not provide a measurement of volume but rather provides a 
measurement of electrical impedance.  When the ratio of the impedance measurement of the 
affected limb compared to the unaffected limb is greater than 1.00, a clinical diagnosis of 
lymphedema is made.  When comparing BIS to other diagnostic techniques, approximately 40%-
60% of patients measured by circumferential means or by self-report went undetected[27]. 
A third common approach to diagnosis of lymphedema is use of optoelectric perometry.  
A perometer uses 360 light beams emitted from both sides of a movable frame positioned 
horizontally above a b ase platform[13, 21].  The space the limb occupies inside the frame 
disrupts the light beams creating a shadow.  The frame is moved up and down along the length of 
each limb and the diameter is measured every 3.1 mm while indirect volume measurements are 
calculated by computer processing software (PeroplusTM)[29].  Perometry is noted as one of the 
most reliable methods; however, several of the disadvantages include difficulty in measuring the 
entire length of each limb including the hands and feet as well as the limited accessibility to use 
such equipment outside of a clinic setting due to its size and complexity[22, 26]. 
Additional radiological studies including CT, MRI, lymphangiography, and 
lymphoscintigraphy also aid in the analysis and diagnosis process[2].  CT and MRI scans show a 
distinctive pattern to the lymphatic system which can help distinguish between differential 
diagnoses.  Lymphangiography is a technique which uses a water soluble solution to observe the 
filling of the lymphatics.  R adiographic images of the filling process are obtained at intervals 
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every several minutes[30, 31].  Unlike lymphangiography, lymphoscintigraphy gathers structural 
and functional data of lymphatic drainage.  Lymphoscintigraphy measures the rate at which 
radiolabelled molecules, which are injected into tissue, are cleared from the lymphatic 
system[32].   
With each measurement technique there are reported difficulties and inconsistencies[26, 
33].  As a result, the reported incidence of women affected by secondary lymphedema following 
breast cancer treatment varies greatly depending upon the population studied and the methods 
used to diagnosis disease.  Reported incidence of breast cancer related lymphedema ranges in the 
literature from 2% to 83%[34].  Currently there is no g old standard method for clinical 
evaluation and diagnosis that is consistent and non-invasive[35]. 
1.4 MANAGEMENT AND TREATMENT 
Presently, there is no cure for lymphedema; however, there are several options for treatment and 
medical management to help control symptoms.  Current physiotherapeutic management 
includes complete or complex decongestive therapy (CDT) and exercise therapy[27].  Additional 
management options include pharmacologic treatment, pneumatic pumps, low level laser 
therapy, and surgery. 
Complex decongestive therapy (CDT) is recognized as one of the optimal strategies for 
management of lymphedema[36].  CDT consists of two phases.  The first phase includes CDT 
therapy which is implemented by a hospital or provided by a lymphedema therapist while the 
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second phase involves at home self-care provided by the patients themselves[37].  CDT therapy 
encompasses four techniques: manual lymphedema drainage (MLD), compression therapy, 
exercises, and patient education regarding skin care[27, 38].   
MLD is a massage technique used to increase lymph flow.  MLD is based on facilitating 
the passage of lymph from affected to unaffected areas of the body[39].  The massage therapy 
typically begins at the neck and trunk area with the goal of assisting in the progression of lymph 
from the main lymphatic pathways and ultimately drainage from the arm.  MLD is typically 
performed for 45-60 minutes four or five times a week during a 2-4 week period.   
Compression therapy includes the use of compression bandages or compression garments 
which contribute to a gradual reduction in volume of the affected limb[3].  Compression 
bandages, made from a gauze sleeve and layer of stretch fabric, are designed to protect and 
constrict the skin.  The bandages compress the covered area averting the counter flow of lymph 
fluid.  Compression garments are similar in function to compression bandages; however, the 
pressure exerted by compression garments is progressive.  Compression garments have a lesser 
amount of compression or resistance located at the proximal end of the arm while the greatest 
amount is located at the distal end of the arm.  Compression bandages and garments are the 
foundation of maintenance therapy after intensive CDT is completed[38].  A recent study 
conducted by King et al. (2011) examined the difference in outcomes when using compression 
bandages compared to compression garments.  The results of the study indicated that use of 
compression bandaging may be more effective in leading to greater limb volume reduction while 
compression garments may result in a better functionality or range of motion for the upper 
extremity[40]. 
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  Patients are encouraged to remain physically active as exercise can improve both their 
range of motion and restore upper extremity function[41].  The internal pressure changes created 
by exercising promote the flow of lymph and lymph drainage.  Shoulder exercises as well as 
weight lifting and strengthening exercises lead to a more rapid recovery of mobility and decrease 
symptoms associated with lymphedema[42, 43].  Patients who began exercise therapy 6-26 
weeks after surgery improved their range of motion without increasing their lymphedema[44].  It 
had been previously accepted that women should avoid and limit the use of their affected arm 
after breast cancer surgery to decrease the risk of lymphedema[45].  More recent data indicates 
that well controlled exercise programs provide benefit to many women.  There are exercise 
guidelines available for patients; however, these guidelines may be modified to fit an 
individual’s needs determined by a baseline assessment prior to surgery[27].  Postoperative 
exercises can improve mobility, shoulder function, overall physical fitness, body composition, 
self-esteem, and quality of life.  Early physiotherapy, initiated for at least one year prior to breast 
cancer surgery, is effective in the prevention of secondary lymphedema onset[36]. 
The final component of CDT includes integration of skin care[27, 38].  Proper skin care 
education promotes daily application of moisturizer as well as appropriate management of nail 
care.  Individuals are cautioned to avoid obtaining any open wounds via cuts, scratches, insect 
bites, etc.  Through patient education of proper skin care the goal is to prevent infection since 
data suggests there is an increased risk of infection and lymphedema associated with skin 
trauma.   
In addition to CDT, many other treatment and management options are available to 
patients including pharmacologic treatment, pneumatic pumps, low level laser therapy, and 
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surgery[3, 6, 46].  The goal of pharmacological therapy by use of benzopryones is to increase 
lymph flow by lowering vascular permeability and decreasing accumulation of protein in lymph 
fluid.  Some substances involved in the pharmacologic treatment of lymphedema remain 
controversial as the use of agents, such as coumarin, can induce hepatic dysfunction[6].  
Pneumatic pumps may consist of single or multiple chambers which inflate and deflate at 
varying levels of pressure[46].  The goal of pneumatic pumps is to promote muscle movement 
and thereby drainage of fluid from the limb.  Low level laser therapy (LLLT) has been used in 
the United States as an accepted form of breast cancer related secondary lymphedema therapy 
since 2007[47].  LLLT uses a low level carbon dioxide laser to decrease the amount of excess 
protein and fluid thus increasing lymphatic flow.  W hen considering surgical treatment for 
lymphedema there are four main options: debulking, liposuction, omental pedicles and 
myocutaneous flap construction, and lymphatic microsurgical preventive healing approach 
(LYMPHA)[6, 48].  Debulking surgery removes excessive skin and tissue and is usually 
performed when there are vast changes in limb size.  Liposuction involves the removal of excess 
adipose tissue.  Omental pedicles and myocutaneous flap interposition allows for the creation of 
a lymphatic bridge which may function in the reestablishment of lymphatic flow[49].  A recently 
developed surgical treatment for lymphedema, LYMPHA, is most appropriate for individuals 
receiving axillary lymph node dissection (ALND)[48].  The LYMPHA procedure includes 
lymphatico-venous anastomoses (LVA) at the time of an ALND procedure[50].  This procedure 
aids in preventing the development of secondary lymphedema.  W ith all surgery there are 
associated risks of complication and therefore most women choose more conservative 
approaches to management.  The majority of women who pursue surgical means to treatment are 
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those which have severe presentation and do not gain improvement or benefit from the 
conservative measures.     
1.5 PREDISPOSITION 
1.5.1 Risk Factors 
Since there is currently no c ure for lymphedema, the most effective means to decrease the 
incidence of this condition is through early detection and risk reduction intervention.  Several 
studies have investigated risk assessment related to multiple predisposing factors involved in the 
development of lymphedema.  Such factors examined include cancer diagnosis and treatment, 
health and behavioral features, as well as patient characteristics.   
It is generally accepted that more advanced cancer typically requiring more extensive 
surgery and exposure to radiation is associated with increased predisposition to lymphedema[34, 
51-53].  A study by Hayes et al. reported a six-fold increase in odds for development of 
lymphedema with extensive surgery[34].  Associations between positive lymph node findings 
and onset of lymphedema have also been reported.  In the same study by Hayes et al. a four-fold 
increase in odds for development of lymphedema was noted when more than twenty lymph 
nodes were removed during surgery.  No confirmed associations have been reported with regard 
to tumor stage, chemotherapy, or surgery of the patient’s dominant side[34, 53, 54].   
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A high body mass index (BMI) indicating obesity is one of the most commonly accepted 
health and behavioral characteristics to have an association with increased risk of 
lymphedema[52, 53].  Both obesity present at the time of diagnosis and weight gain post 
treatment is believed to be contributory[52].  Obesity results in an increased risk for lymphedema 
onset due to the increased stress on the lymphatic system.  In addition to obesity, infection and 
limb injury[51-53] as well as the subjection to lower pressure during air travel[51] have also 
been associated with increased risk of lymphedema onset.  Circulatory diseases, such as 
hypertension, may also play a role in increasing risk for lymphedema; however, the data 
supporting this hypothesis is inconsistent[51, 52].    
In regards to patient characteristics, age is one of the most studied factors with many 
studies reporting mixed findings[34, 52].  D ifferent reports indicate a greater association with 
women of a young age (<50 years), older age (> 50 years), and some with no association at all.  
However, in the majority of studies the consensus is that age does not play a contributory role in 
lymphedema onset.  In a s tudy by Hayes, et al. women with young children and of lower 
socioeconomic status were found to have a decreased risk in which the odds of lymphedema 
development were reduced by five- to ten-fold[34].  From the authors’ data, this risk reduction is 
based on the idea that such women find themselves using their treated side more often when 
caring for young children and that lower socioeconomic status can be associated with 
occupations involving more manual labor.  T hese findings support the theory that physical 
activity and use of an individual’s treated side does not increase risk of lymphedema but rather 
improves arm symptoms. 
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1.5.2 Genetic Etiology 
Several studies have examined the genetic etiology of primary and secondary lymphedema 
development and function.  Lymphedema is a heterogeneous condition which can exist as part of 
a genetic syndrome or as an isolated occurrence.  Disease causing mutations account for few 
lymphedema cases; however, continued study of genetic etiology may reveal new insights and 
findings of lymphatic disease[55].   
Milroy’s disease is an autosomal dominant condition characterized by congenital 
lymphedema[55].  Mutations in vascular endothelial growth factor C receptor (VEGFR3; FLT4) 
are responsible for Milroy’s Disease[56].  Milroy’s disease has variable expressivity and 
typically presents as a bilateral manifestation affecting the lower limbs.  Approximately 80-90% 
of individuals with an identified VEGFR3 mutation develop lymphedema before the age of 
three[57].   
Hypotrichosis-lymphedema-telangiectasia syndrome is characterized by lower limb 
lymphedema, telangiectasias, and hypotrichosis.  M utations in SRY-box 18 ( SOX18) are 
responsible for this condition[55, 56].  Hypotrichosis-lymphedema-telangiectasia syndrome has 
been observed with both autosomal dominant and autosomal recessive forms of inheritance[58].   
Lymphedema-distichiasis syndrome is an autosomal dominant condition characterized by 
lower limb lymphedema and distichiasis and is caused by mutations in FOXC2 (MFH1)[55].  
FOXC2 is believed to play a critical role in the institution of a smooth muscle cell-free lymphatic 
network.  Truncating FOXC2 mutations disrupt activation of gene transcription and have been 
shown to result in broad phenotypic variability within families[59].  F OXC2 mutations are 
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primarily responsible for lymphedema-distichiasis; however, based on t his broad phenotypic 
observation, mutations in this gene are also believed to contribute to other lymphedema 
phenotypes.   
Hennekam syndrome is an autosomal recessive condition characterized by severe 
congenital lymphedema, intestinal lymphangiectasia, seizures, growth retardation, and facial 
anomalies[60, 61].  Within Hennekam syndrome, lymphedema is most commonly gradual and 
progressive primarily affecting the limbs and bowels but can also be observed in the face and 
genitals[62].  Additional defects associated with this syndrome include congenital glaucoma, 
congenital heart defects, vascular anomalies, craniosynostosis, renal malformations, and hearing 
loss.  In several individuals with Hennekam syndrome homozygous and compound heterozygous 
mutations have been identified in the CCBE1 gene located at chromosome 18q21[63].  The 
CCBE1 (collagen and calcium-binding EGF-domain-1) gene is involved in the extracellular 
matrix and is not expressed in endothelial lymph vessel cells.  It is believed that CCBE1 plays a 
regulatory role in the early migratory patterns of lymphatic development since ccbe1 is 
expressed in the migratory routes of endothelial cells destined for lymphatic vessels in zebrafish. 
Emberger syndrome is an autosomal dominant disorder characterized by primary 
lymphedema with myelodysplasia[64, 65].  Myelodysplasia predisposes affected individuals to 
the development of acute myeloid leukemia.  Mutations in GATA2 are responsible for Emberger 
syndrome.  GATA2 is a transcription factor responsible for the control and management of 
hematopoietic differentiation and vascular development.   
Microcephaly-Lymphedema-Chorioretinopathy is an autosomal dominant condition 
presenting with a wide spectrum of CNS and ocular findings[66].  Microcephaly is considered 
 17 
 
 
the critical component of this syndrome and can range from mild to severe.  Lymphedema 
associated with this syndrome presents as the congenital form and typically affects the dorsa of 
the feet.  Variable visual deficiencies have been observed as a result of chorioretinal 
dysplasia[67].  Mutations in the KLF11 gene are found to be causal of Microcephaly-
Lymphedema-Chorioretinopathy[66].  The KLF11 gene encodes EG5 which is a kinesin motor 
known to contribute to spindle formation.  Mutations in the KLF11 gene are expected to disrupt 
protein function underlining the importance of spindle assembly in CNS development and 
function. 
Ferrell et al. investigated 25 candidate genes in families with primary lymphedema[56].  
Results showed causative mutations in the genes FABP4, NRP2, SOX17, and VACM1.  In 
addition, Finegold et al. identified mutations in HGF (hepatocyte growth factor) and MET (high 
affinity hepatocyte growth factor receptor) in individuals with primary and secondary 
lymphedema[68].  HGF/MET is highly expressed in lymphatic endothelial cells and has a wide 
range of biological functions including roles in cell growth, mobility, differentiation, and 
intracellular junctions.  Truncating and missense mutations were reported in both primary and 
secondary lymphedema cases.   
Mutations in the connexin 47 ( GJC2) gene were also observed in several primary 
lymphedema families as well as women with secondary lymphedema following breast cancer 
therapy.  T he role of the connexin genes involves the formation of gap junctions which are 
believed to contribute to the progression of lymphatic flow and function.  In primary 
lymphedema families, a total of 6 out of 150 probands were identified with a unique connexin 47 
missense mutation[69].  Two of the probands were part of large families in which segregation of 
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the mutation with the associated lymphedema phenotype was observed.  In a case-control study 
designed to investigate secondary lymphedema, 188 women diagnosed with breast cancer were 
screened for mutations in connexin 47 (GJC2), FOXC2, HGF, MET, and FLT4 (VEGFR3)[70].  
Connexin 47 m utations were identified in 4 women with secondary lymphedema following 
breast cancer treatment.   
The finding of HGF and MET mutations first raised the possibility of a genetic 
predisposition to secondary lymphedema and with the recent finding of connexin 47 mutations a 
genetic predisposition to the development of secondary lymphedema was confirmed.  Previously 
identified genes contribute to our understanding of genetic risk factors involved with 
lymphedema; however, these genes only account for a few secondary lymphedema cases.  
Continuing advances can aid in the effort for early detection and prevention; in turn, further 
studies examining genetic etiology are warranted.   
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2.0  SPECIFIC AIM OF THE STUDY 
The goal of this study is to further investigate the significance of additional connexin genes, 
specifically connexin 40, in the development of secondary lymphedema.  Connexins 37, 40, 43 
and 47 are all expressed in the lymphatics and thus provide rationale for investigating other 
connexins in lymphedema.  Mutations in the connexin 47 ( GJC2) gene have been previously 
identified as a causal and/or predisposing factor in the development of primary and secondary 
lymphedema[69, 70].  The exact mechanism by which connexin 47 m utations increase 
susceptibility to lymphedema is unknown; however, it is proposed that such mutations disrupt 
gap junction communication resulting in impaired lymphatic flow.  The previously identified 
mutations support genetic susceptibility to secondary lymphedema onset and warrant further 
consideration of additional connexin genes.  Overall, there are twenty different connexins which 
can form gap junctions[71].  Gap junctions function as intercellular communication channels 
between cells allowing for the passage of substances between cell membranes.  Expression of 
connexins is highly regulated and the mechanism by which regulation is maintained is not clearly 
understood.   Gap junctions are involved in a variety of different tissues and are required for 
many developmental and physiologic processes[72].   
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Aim: The aim of this study was to determine if individuals with secondary lymphedema 
following breast cancer treatment have mutations in the connexin 40 (GJA5) gene.   
Hypothesis: The hypothesis for this study is that other connexin genes, in addition to 
connexin 47, play a contributory role in lymphedema development and that in a subset of women 
treated for breast cancer who developed secondary lymphedema, inherent mutations in the 
connexin 40 (GJA5) gene will be identified by gene sequence analysis. 
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3.0  MATERIALS AND METHODS 
3.1 STUDY DESIGN 
The breast cancer secondary lymphedema research study was initially submitted to and approved 
by the Institutional Review Board of the University of Pittsburgh.  This case-control study is a 
comparison of the occurrence of lymphedema in women with and without a diagnosis of 
secondary lymphedema following breast cancer treatment.   
Women were recruited and screened to determine eligibility.  Screening questions were 
asked by telephone prior to enrollment.  All appointments for enrolled and consented patients 
were held in the Clinical Translational Research Center (CTRC) at Magee Women’s Hospital of 
the University of Pittsburgh Medical Center (UPMC).  Women clinically diagnosed with 
lymphedema by a physician or physical therapist are defined as cases and women who have not 
developed lymphedema and are at risk for development are defined as controls.   
Within the study there are two components: a retrospective analysis and a prospective 
analysis.  The retrospective study received IRB approval September 5th, 2000 under IRB#960639 
and is no longer accruing patients.  The cohort of individuals enrolled in the retrospective study 
received breast cancer treatment between the years 1988 and 1999.  The prospective study 
received IRB approval March 8th, 2007 (PRO06080011) and is currently open to enrollment with 
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the goal of accruing 750 participants.  The individuals enrolled in the prospective study received 
breast cancer treatment within the past several years.  Women from the prospective study were 
recontacted annually to determine if their lymphedema status had changed since the time of 
initial enrollment in the study.  If a woman developed lymphedema since the initial time of 
contact and enrollment, she was appropriately reclassified as a case.  DNA samples were 
obtained from all individuals in both the retrospective and prospective groups.   
3.2 SUBJECT RECRUITMENT 
As described in a master’s thesis by Roxanne Miller, 2003, potential participants in the 
retrospective study were recruited via letters mailed from Magee Women’s Hospital and 
contacted by phone[73].  Interested individuals were eligible for enrollment if they were 
diagnosed with breast cancer between the years 1988 and 1999.  One hundred and sixty potential 
cases and five hundred potential controls were contacted through the Physical Therapy and 
Medical Records Department at Magee Women’s Hospital.  A total of 64 cases and 63 controls 
were successfully recruited, enrolled, and consented to participate in the retrospective study.  
Participants completed a medical history questionnaire verifying their breast cancer diagnosis 
and lymphedema diagnosis (if applicable).  Family history was also obtained.  A DNA sample 
was collected through a 30cc blood sample or buccal swab.  Sequencing of the connexin 40 
(GJA5) gene was analyzed for 52 cases and 52 controls in the retrospective study. 
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Potential participants in the prospective study were recruited from the University of 
Pittsburgh Breast Cancer Program from flyers and brochures located in Magee Women’s 
Hospital, referral from the genetics of post mastectomy pain study directed by Inna Belfer, M.D., 
and direct contact in the medical oncology and lymphedema clinics.  The potential participants 
directly contacted in clinic were first approached by a physician or nurse to gain permission for a 
researcher to speak with them in regards to the study.  Individuals who gave permission were 
provided details of the research study by the researcher.  Participants were asked to inform 
family members of the study and those who initiated contact were given the opportunity to 
participate as well.  A total of 185 individuals enrolled and consented to participate in the study 
including 43 cases, 120 controls, 8 unsure, and 14 family members.  Participants classified as 
unsure reported having variable degrees of swelling post breast cancer treatment; however, at the 
present time it was uncertain if the swelling was lymphedema or related to post-surgical 
swelling.  None of the participants in the unsure group had an official diagnosis of lymphedema 
by a health care professional.  A standardized medical questionnaire was completed and family 
history obtained for all individuals.  Participants also underwent a series of three measurement 
analyses using circumferential measurement of the limbs, BIS, and Perometry.  All participants 
had blood samples drawn for DNA analysis.  In the event a blood sample could not be obtained, 
an alternative method using an Oragene DNA® saliva kit was utilized.  Sequencing of the 
connexin 40 (GJA5) gene was analyzed for 39 cases and 116 controls in the prospective study. 
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3.3 LABORATORY PROCEDURES 
DNA was isolated from ETDA anti-coagulated peripheral blood by the salting out procedure 
described by Miller et al. [74].  DNA extraction from the saliva samples was performed using an 
Oragene DNA® kit.  Amplification and sequencing primers were synthesized based on reported 
human connexin 40 (GJA5) cDNA sequence NM_005266.  The sequence was downloaded from 
GenBank and flanking primers were designed to amplify the target sequence.  The following 
primers were used to screen for the connexin 40 (GJA5) gene: 
 2F, 5’-CCATTGGATGGATGGATC-3’  
2R, 5’-CCGTAGATGAAGTACTGG-3’ (54°C Ta; 1.5 mM Mg++)  
2F2, 5’-GGAAGGGAATGGAAGGAT-3’  
2R3, 5’-CAGTTCAGAAGGGACACG-3’ (54°C Ta; 1.5 mM Mg++) 
Sequences were amplified using the previously listed primers by a polymerase chain 
reaction.  The PCR technique utilized an Invitrogen Taq at an annealing temperature of 54°C.    
Several templates were amplified using a QIAGEN Multiplex PCR kit.  T he QIAGEN kit 
provided greater sensitivity and specificity with a built-in hot start and more efficient 
amplification of G-C rich regions.  The initial denaturing step was followed by 94 cycles at 30 
seconds each, 54 cycles at 30 seconds each, and 72 cycles at 45 seconds each.   
A shrimp alkaline phosphatase and Exonuclease I were used to treat the amplimers.  The 
amplimers were sequenced in both directions using ABI Big Dye 3.1 chemistry (Applied 
Biosystems, Foster City, California 94404).  An ABI 3730 DNA analyzer was used to sequence 
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the fragments.  Sequences were aligned using Sequencher V5.0 software (Gene Codes Corp., 
Ann Arbor, Michigan 48108).   
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4.0  RESULTS 
4.1 GENE SEQUENCING ANALYSIS 
Sequence analysis of the connexin 40 (GJA5) gene was completed for 52 cases and 52 controls 
in the retrospective study and 39 cases and 116 controls in the prospective study.  The connexin 
40 (GJA5) gene is located on c hromosome 1q21.1 encoding 358 amino acids.  T he gene is 
comprised of 2 exons in which exon 1 is noncoding.   
Sequencing analysis identified a common single nucleotide variant in a noncoding region 
of the gene.  This variant was confirmed in 1 control in the retrospective study and 3 controls in 
the prospective study.  The variant, located at base pair 15,268 is a G  A nucleotide change.  
This variant is validated and catalogued as rs16192141 in the National Center for Biotechnology 
Information (NCBI) database.       
No other variants or mutations were identified in any of the cases or controls screened for 
connexin 40 (GJA5). 
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4.2 DESCRIPTIVE STATISTICS 
Demographic and risk factor exposure information was collected from the medical history 
questionnaires completed by all participants in both retrospective and prospective groups.  
Demographic information includes age at enrollment, age at breast cancer diagnosis, age at 
lymphedema diagnosis, BMI, and ethnicity.  The timing of onset of lymphedema after a breast 
cancer diagnosis was also examined in all cases.  R isk factor information contains treatment 
variables of mastectomy and radiation therapy in addition to self-reported exposures including 
blood draw, blood pressure measurement, cat scratch, cut, insect bite, manicure, and sunburn.  
Statistical analysis was performed using SPSS Statistics 20 and SAS 9.3 for Windows.   
4.2.1 Demographic Analysis 
Table 1 and Table 2 contain the respective demographic information for ethnicity, age, age at 
breast cancer diagnosis, age at lymphedema diagnosis, and BMI for retrospective and 
prospective groups.     
According to the National Heart, Lung, and Blood Institute, classification of BMI (kg/m2) 
measurements less than 18.5 is underweight, between 18.5-24.9 is normal, between 25.0-29.9 is 
overweight, and greater than or equal to 30.0 is obese[75].  The average BMI for cases in the 
retrospective group is 28.8 and in the prospective group is 28.7 which are both classified within 
the upper limit of the overweight category.   
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Table 1. Retrospective Group: Demographic Variable Means and Standard Deviations 
 Cases 
N=64 
Controls 
N=63 
Ethnicity (% Caucasian) 56/64 (87.5%)  62/63 (98.4%)  
Age (range) 59.4 (38-85) 
SD=10.39 
57.0 (33-78) 
SD=8.53 
Age at Breast Cancer Diagnosis (range) 52.6 (30-74) 
SD=10.01 
51.4 (29-74) 
SD=8.83 
Age at Lymphedema Diagnosis (range) 55.0 (32-82) 
SD=10.42 
- 
BMI (range) 28.8 (19.6-48.4) 
SD=6.25 
27.05 (19.2-41.6) 
SD=5.00 
 
Table 2. Prospective Group: Demographic Variable Means and Standard Deviations 
 Cases 
N=43 
Controls 
N=120 
Unsure 
N=8 
Ethnicity (% Caucasian) 41/43 (95.3%) 110/120 (91.7%) 8/8 (100%) 
Age (range) 58.3 (38-93) 
SD=12.85 
53.8 (22-76) 
SD=9.77 
57.8 (40-75) 
SD=12.89 
Age at Breast Cancer Diagnosis 
(range) 
53.5 (34-77) 
SD=11.03 
52.0 (20-75) 
SD=9.69 
56.9 (39-71) 
SD=12.51 
Age at Lymphedema Diagnosis 
(range) 
56.0 (37-78) 
SD=11.70 
- - 
BMI (range) 28.7 (19.7-44.5) 
SD=6.33 
28.1 (17.5-48.7) 
SD=5.80 
30.0 (24.1-37.4) 
SD=4.55 
 
Independent sample t-tests were carried out to investigate the differences in demographic 
variables between cases and controls.  The cases and controls from both the retrospective and 
prospective groups were combined to examine differences between the total number of cases and 
controls involved in the study.  Independent t-tests shown in Table 3 reveal a significant finding 
between the age of cases and controls at the time of enrollment.  With a p -value of p=0.002 
(p<0.05, two-tailed) there is a significant difference between the ages of cases and controls with 
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an older age being observed in the cases compared to the controls.  Differences between cases 
and controls for age at breast cancer diagnosis and BMI are not significant (p>0.05, two-tailed). 
 
Table 3. Retrospective and Prospective Groups Combined: Independent Samples T-Test for 
Equality of Means of Demographic Variables 
  N Mean Standard 
Deviation 
t p 
 
Age 
 
Cases 
Controls 
 
107 
183 
 
59.0 
54.9 
 
11.40 
9.46 
 
-3.120 
 
0.002* 
 
Age at Breast Cancer 
Diagnosis 
 
Cases 
Controls 
 
107 
183 
 
53.0 
51.8 
 
10.39 
9.38 
 
-1.002 
 
0.317 
 
 
BMI 
 
Cases 
Controls 
 
107 
183 
 
28.8 
27.8 
 
6.28 
5.56 
 
-1.482 
 
0.139 
 
The timing of secondary lymphedema onset after breast cancer diagnosis was examined.  
The cases from the retrospective group (N=64) and the prospective group (N=43) were combined 
to determine the distribution of onset.  The majority of women in this study reported 
lymphedema onset occurring within 1-2 years following a diagnosis of breast cancer.  It is 
known that lymphedema can occur weeks to years after surgery.  Many controls involved in the 
prospective study were enrolled within 1 year of their breast cancer surgery; therefore, they are 
still at risk to develop lymphedema.  O ver time, controls who develop lymphedema will be 
reclassified as cases thus altering the distribution analysis. 
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Figure 1. Timing of Lymphedema Onset After Breast Cancer Diagnosis 
(Retrospective and Prospective Cases, N=107) 
4.2.2 Exposures and Risk Factor Analysis 
Self-reported exposures and risk factors for cases and controls are listed in table 4 for the 
retrospective group and in table 5 for the prospective group.  Participants were asked to indicate 
which type of breast cancer treatment they had undergone and which risk factors they had 
exposure to after surgery.  Fisher exact tests were carried out to investigate differences between 
cases and controls in the retrospective group and between cases, controls, and those classified as 
unsure in the prospective group. 
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In table 4 there is a s ignificant difference between retrospective cases and controls and 
reported manicure exposure.  In this group, 13/64 (20%) cases and 25/63 (40%) controls reported 
having a m anicure.  W ith a p -value of p=0.021 there is a significant difference (p<0.05, two-
tailed) in that the control group has a higher reported number of manicure exposures.   
In table 5 there is a significant difference between prospective cases, controls, and those 
classified as unsure for reported radiation exposure and insect bite exposure.  In this group 33/43 
(77%) cases, 64/120 (53%) controls, and 4/8 (50%) unsure reported having radiation therapy.  
With a p-value of p=0.019 there is a significant difference (p<0.05, two-tailed) with cases having 
a higher number of participants receiving radiation therapy.  In addition, 15/43 (35%) cases, 
22/120 (18%) controls, 0/8 (0%) unsure reported having an insect bite exposure.  With a p-value 
of p=0.029 there is a s ignificant difference (p<0.05, two-tailed) with cases having a h igher 
number of reported insect bite exposures.  Both radiation therapy and insect bite exposure are 
known risk factors for lymphedema development. 
 
Table 4. Retrospective Group: Self-Reported Risk Factor Exposure 
 Cases 
N=64 
Controls 
N=63 
 
 
p 
Mastectomy 27 23 0.587 
Radiation 52 46 0.297 
Blood Draw 8 5 0.560 
Blood Pressure 7 6 1.00 
Cat Scratch 6 11 0.203 
Cut 20 23 0.577 
Insect Bite 17 22 0.340 
Manicure 13 25 0.021* 
Sunburn 12 17 0.297 
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Table 5. Prospective Group: Self-Reported Risk Factor Exposure 
 Cases 
N=43 
Controls 
N=120 
Unsure 
N=8 
 
 
p 
Mastectomy 19 46 5 0.339 
Radiation 33 64 4 0.019* 
Blood Draw 4 24 0 0.138 
Blood Pressure 5 25 0 0.205 
Cat Scratch 5 14 0 0.828 
Cut 16 33 1 0.309 
Insect Bite 15 22 0 0.029* 
Manicure 10 26 0 0.412 
Sunburn 5 12 0 0.812 
 
The total number of reported exposures was investigated using an analysis of variance 
(ANOVA).  ANOVA analysis was carried out using the total number of reported exposures in 
the retrospective and prospective groups.  There are no statistically significant differences 
(p>0.05, two-tailed) in the average number of exposures between cases and controls in the 
retrospective group and between cases, controls, and those classified as unsure in the prospective 
group.  
Table 6. Retrospective Group: Analysis of Total Number of Risk Factor Exposures Reported 
 N Mean Standard 
Deviation 
F p 
Cases 64 2.53 1.583 1.097 0.297 
Controls 63 2.83 1.582   
 
Table 7. Prospective Group: Analysis of Total Number of Risk Factor Exposures Reported 
 N Mean Standard 
Deviation 
F p 
Cases 43 2.60 1.591   
Controls 120 2.22 1.583 2.761 0.066 
Unsure 8 1.25 0.886   
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5.0  DISCUSSION 
With advances in breast cancer detection and treatment over time, the life expectancy of many 
women has improved raising the importance of quality of life post-surgery.  The exact incidence 
of secondary lymphedema is unclear due to the lack of universally accepted  clinical criteria 
defining a lymphedema diagnosis and multiple methods of measurement reported in medical 
literature[16].  Lymphedema being a common complication following breast cancer treatment 
can result in physical impairment as well as psychological morbidity[11].  Women who develop 
secondary lymphedema may experience variable degrees of functional impairment, pain, 
weakness, stiffness, numbness, and increased risk of infection.  Psychological distress may also 
accompany lymphedema onset in many affected women.  Several studies have shown that 
women with lymphedema develop higher levels of social and psychological morbidity than 
women who do not develop secondary lymphedema[76].  Anxiety, depression, social avoidance, 
and self-consciousness may all contribute to the psychological distress experienced by many of 
these women.   
Unfortunately, there is no cure for lymphedema.  Several management options exist to 
help diminish arm symptoms; however, not all women find benefit from the available treatments.  
Efforts towards the treatment and management of lymphedema are most effective when 
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implemented early[11].  It is therefore important to clarify predisposing risk factors and to better 
understand genetic etiology in the effort for early detection and efficient intervention.  
5.1 GENE SEQUENCING 
Initial genetic studies contributed to the current understanding of primary lymphedema while 
more recent discoveries have expanded our knowledge of the genetic etiology of secondary 
lymphedema.  M utations in HGF, MET, and connexin 47 ha ve been recently identified in 
secondary lymphedema patients[68, 70].  Connexins are gap junctions responsible for facilitating 
cell to cell communication.  Connexins are also found to be highly expressed in the lymphatics 
warranting further investigation of additional connexin genes.  The primary aim of this study was 
to identify mutations in the connexin 40 (GJA5) gene which may increase susceptibility to 
development of secondary lymphedema in women treated for breast cancer.  It was hypothesized 
that previously unidentified mutations would be found in the connexin 40 ( GJA5) gene of 
women who developed lymphedema post breast cancer treatment.  The connexin 40 (GJA5) gene 
was sequenced in a cohort of 259 (N=91 cases, N=168 controls) women diagnosed with breast 
cancer with and without secondary lymphedema.  A previously recognized single nucleotide 
variant was identified in the noncoding region of four women with breast cancer and without 
lymphedema.  No previously unidentified mutations were identified in the connexin 40 (GJA5) 
gene of women treated for breast cancer with secondary lymphedema which is inconsistent with 
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our hypothesis.  Despite the negative findings in this study, further investigation of additional 
connexin genes is still warranted given their involvement with the lymphatic system.   
5.2 DEMOGRAPHIC AND RISK FACTOR INFORMATION ANALYSIS 
Demographic and self-reported risk factor information was collected from all participants 
involved in the study.  Statistical analysis of such data revealed several statistically significant 
differences between cases and controls.  Overall, the age at time of enrollment was significantly 
higher in cases than in the controls (p=0.002).  In regards to predisposing risk factors, there was a 
statistically significant difference between cases and controls for which reported radiation 
exposure (p=0.019) and insect bite exposure (p=0.029) was greater in cases compared to 
controls.  R adiation therapy and insect bite exposure are risk factors reported in the literature 
associated with increased risk for development of lymphedema.  A  study by Niwinski et al. 
reported a lymphedema incidence of 10% among women receiving radiation therapy in breast-
conserving surgery while another study by Bani et al. reported a lymphedema incidence of 30% 
among women treated with radiation therapy as part of breast cancer treatment[27, 77].  In our 
study a total of 85 out of 199 ( 42.7%) women who reported receiving radiation treatment 
developed lymphedema.  In regards to the insect bite exposure, breast cancer patients are advised 
to protect their skin and to avoid cutaneous skin trauma (cuts, insect bites, etc.) as a prevention 
measure[78].  In our study, a total of 32 out of 76 (42.1%) women who reported having an insect 
bite exposure developed lymphedema.   
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The timing of lymphedema onset after breast cancer diagnosis was also evaluated.  It is 
known that lymphedema onset can occur weeks to years after breast cancer therapy.  A study of 
282 patients found the average timing of lymphedema onset was 14 months after treatment with 
a range of 2 to 92 months[79].  As reported in the literature the onset can be gradual or rapid and 
the majority of patients experience lymphedema onset within the first three years after breast 
cancer surgery[80, 81].  It is estimated that 75% of secondary lymphedema cases develop 
lymphedema within 2 years of breast cancer treatment and 90% within 3 years[82].  In our study, 
out of a total of 107 enrolled cases 40 (37%) women experienced lymphedema onset within the 
same year as their diagnosis, 31 (29%) experienced onset after the second year following a 
cancer diagnosis, and 14 (13%) experienced onset after the third year following a cancer 
diagnosis.   
5.3 LIMITATIONS OF STUDY AND FUTURE CONSIDERATIONS 
Within this study controls are still considered to be at risk for development of lymphedema since 
onset can occur multiple years after surgery.  It is possible that in the future current controls may 
develop lymphedema and would be reclassified as cases thus altering the current analyses.  In 
addition, within the prospective cohort several individuals had arm symptoms but did not have a 
clinical diagnosis of lymphedema.  These individuals were classified in an unsure group.  With 
proper evaluation and future follow-up we would expect to reclassify each subject as either a 
case or a control.   
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There is presently no standard clinical definition of lymphedema; therefore, for the 
purposes of this study a clinical diagnosis of lymphedema by a healthcare professional was used 
to define lymphedema cases.  Measurement analyses had been performed on all subjects 
involved in the study.  The measurement analyses obtained were unfortunately inconsistent and 
inaccurate.  In the future, with the obtainment of reliable measurements such analyses will aid in 
the appropriate classification of cases and controls.   
Additionally, risk factor exposure information was subject to recall bias.  R ecall bias 
occurs when information is differentially misclassified between cases and controls.  With recall 
bias individuals who have experienced disease may tend to think about possible “causes” of the 
outcome which can lead to differential recall.  A ll risk factor exposures (blood draw, blood 
pressure, cut, cat scratch, insect bite, and sunburn) were collected based on p atient provided 
information and therefore subject to recall bias. 
Secondary lymphedema is not only a problem for patients treated for breast cancer but 
also for patients treated for other cancers such as malignant melanoma and gynecological 
malignancies.  Research on lymphedema development secondary to additional malignancies is 
limited compared to breast cancer.  T he prevalence of secondary lymphedema following 
gynecological malignancy treatment ranges from 1-49%[83].  Post treatment edema of the lower 
limb is believed to occur at a similar frequency compared to lymphedema onset post breast 
cancer therapy.  Research also suggests risk factors related to lower limb secondary lymphedema 
are similar to those reported in upper extremity secondary lymphedema[84].  Genetic variation 
may also be a contributing factor to the development of lower limb edema secondary to 
gynecological malignancy.  Gynecological malignancy patients have recently been added to the 
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IRB approved protocol for this study.  In future studies, gynecologic malignancy subjects will be 
sequenced for candidate genes to identify underlying genetic variation responsible for or 
predisposing to secondary lymphedema development.  
Given the evidence suggesting connexins play an important role in lymphatic regulation 
as well as the previously identified connexin 47 mutations in secondary lymphedema cases; 
studies of additional connexin genes are warranted.  Additional studies and genetic findings will 
further support that genetic variation within specific genes is involved in secondary lymphedema 
onset.    
5.4 PUBLIC HEALTH SIGNIFICANCE 
Lymphedema has become one of the most feared long term complications after breast cancer 
treatment[11].  Secondary lymphedema is an incurable, progressive, and debilitating disease 
affecting approximately 2-3 million people in the United States of which 600,000 a re women 
who received breast cancer treatment[8, 85].  It is estimated that out of two million women with 
breast cancer in the United States, at least one in every four women is likely to develop 
lymphedema within 11 years[16].  Our understanding of disease etiology is unclear and further 
complicated by inconsistent reports of incidence as well as conflicting evidence regarding 
personal and cancer treatment related risk factors.  Finding heritable components to the 
development of secondary lymphedema following cancer therapy will allow early identification 
of women who are at risk for developing lymphedema post treatment.  Currently, there is no 
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model to successfully predict which women are at high risk for lymphedema onset.  W ith the 
identification of women predisposed to developing this complication, earlier diagnosis and 
management can be offered with the anticipation of an increased benefit from treatment and even 
prevention.   
5.5 CONCLUSIONS 
Secondary lymphedema is a chronic condition that occurs worldwide in breast cancer patients.  
This condition broadly impacts function and quality of life of many cancer survivors.  Previous 
studies have identified mutations in the HGF, MET, and Connexin 47 (GJA5) genes which are 
believed to be causal and/or predisposing factors in the development of secondary lymphedema.  
This study further investigated the role connexins play in lymphedema by sequencing of the 
connexin 40 ge ne in a case-control study.  Despite the fact that we did not find previously 
unidentified mutations in the connexin 40 gene within this population, further investigation of 
additional connexin genes is warranted due to their previously identified role in lymphatics.  
Studying the genetics of lymphedema will aid in the effort to better predict who is at risk for 
lymphedema onset after cancer treatment.  We expect that such discoveries will contribute to an 
earlier diagnosis, improved treatment, and possible prevention. 
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University of Pittsburgh 
Institutional Review Board 
3500 Fifth Avenue 
Ground Level 
Pittsburgh, PA 15213 
(412) 383-1480 
(412) 383-1508 (fax) 
http://www.irb.pitt.edu 
 
 
Memorandum 
    
To: DAVID FINEGOLD, MD 
From: MARGARET HSIEH, MD, Vice Chair 
Date: 3/8/2007  
IRB#: PRO06080011 
Subject: Familial susceptibility for lymphedema secondary to breast cancer therapy.  
  
 
Your research study was approved by the Institutional Review 
Board, Committee B, which met on 2/13/2007.  
 
Please note the following information: 
Approval Date:  3/8/2007 
Expiration Date:  2/12/2008 
Please note that it is the investigator’s responsibility to report to the IRB any 
unanticipated problems involving risks to subjects or others [see 45 CFR 
46.103(b)(5) and 21 CFR 56.108(b)].  The IRB Reference Manual (Chapter 3, 
Section 3.3) describes the reporting requirements for unanticipated problems 
which include, but are not limited to, adverse events.  If you have any 
questions about this process, please contact the Adverse Events Coordinator 
at 412-383-1480. 
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The protocol and consent forms, along with a brief progress report must be 
resubmitted at least one month prior to the renewal date noted above as 
required by FWA00006790 (University of Pittsburgh), FWA00006735 
(University of Pittsburgh Medical Center), FWA00000600 (Children’s Hospital 
of Pittsburgh), FWA00003567 (Magee-Womens Health Corporation), 
FWA00003338 (University of Pittsburgh Medical Center Cancer Institute). 
Please be advised that your research study may be audited periodically 
by the University of Pittsburgh Research Conduct and Compliance 
Office. 
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 QUESTIONNAIRE: SECONDARY LYMPHEDEMA STUDY 
 
Name:                                                   
Address:              
 
                                                                                                                                                                              
Phone (Home)                                                               (Work)            
 
(Cell)           
 
 E-Mail:                                                                                                                    
Gender:    Male    Female Birth Date:         /        /            
 
What is your: Height?                                 Weight?        
 
What is your ethnic background/ancestry? (examples: German, French, Cuban, Japanese, Ashkenazi Jewish): 
               
I. Cancer, Surgical, and Medical History 
 
(For women with breast cancer) 
When were you diagnosed with breast cancer?    Year:                                             Age at diagnosis:     
Was the cancer in your:   Left Breast     Right Breast      Both breasts?       
Did it recur?     Yes     No  If recurred, what year?___________________ 
What treatments have you had for breast cancer? (Check all that apply, even if it was after a recurrence): 
  Lumpectomy        Lymph Node Removal 
 Chemotherapy       Radiation   
  Unilateral mastectomy     Bilateral mastectomy     Breast Reconstruction   
 Tamoxifen,or other hormonal therapy      Please list            
How many lymph nodes were removed?   ___________________      
(For all participants) 
Have you ever been diagnosed with any other type of cancer?      Yes       No 
If Yes, Type of cancer:                                                                   Age at diagnosis:            
Location of cancer:           Treatment:      
Have you ever had vascular surgery? (surgery on blood or lymphatic vessels)   Yes      No      Not Sure 
If Yes: a)    Why did you have surgery?             
b) What kind of surgery?            
c) How old were you?               
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Have you ever had any other type of surgery not listed above?    Yes      No      Not Sure 
If Yes: a)    Why did you have surgery?             
b)    What kind of surgery?             
d) How old were you?            
Please check (and give age at diagnosis) if you have you ever been diagnosed with any of the following conditions: 
  Diabetes (Age at Diagnosis:                           )  Congestive Heart Failure (Age at Diagnosis:                    ) 
  Varicose Veins (Age at Diagnosis:                 )  Rheumatoid Arthritis (Age at Diagnosis:                          ) 
  Phlebitis (Age at Diagnosis:                           )  Liver Disease or Hepatitis (Age at Diagnosis:                   ) 
Have you had any other diseases, major illnesses, health problems or hospitalizations not listed? 
 Yes      No     Not Sure 
If yes, please list each disease and the age at which it was diagnosed. 
a)               
b)                
c)                
 
(if female) 
 
How old were you when your menstrual periods began?                                          
How many pregnancies have you had?                                                                                                      N/A 
How many children do y ou have? ___________________________________________________________   N/A  
How old were you, at the time of each birth?                                                                                                   N/A 
How old were you when you underwent menopause?                                                                                     N/A 
Was menopause surgically induced (example: hysterectomy)?     Yes    No      Not Sure    N/A 
 
(For women with breast cancer) 
Before you developed breast cancer, how did your level of physical activity compare to other individuals your 
age? 
    Much Less Active    Little Less Active    About as Active    Little More Active    Much More 
Active 
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After your breast cancer treatments, how did your level of physical activity compare to your activity level before 
you  developed cancer? 
    Much Less Active    Little Less Active    About as Active    Little More Active    Much More 
Active 
After your breast cancer treatments, did you ever have any of the following on the arm/hand on the SAME side that 
you had surgery for breast cancer?  (Please check all that apply) 
  Blood pressure reading     Blood draw      Wear a prosthesis     Manicure 
  Sunburn or other burn          Cut         Insect bite         Cat scratch 
Since your cancer treatment(s), how many round-trip airplane flights have you taken?                         
On how many of those flights did you wear a compression sleeve on your arm?                                                 N/A 
 
 
II.  Lymphedema is swelling, usually of an arm or leg, due to an accumulation of fluid 
under the skin and caused by a poorly functioning lymphatic system.  Lymphedema can be 
inherited (primary) or acquired (secondary).  For the following questions, please check all 
answers that apply, and give the closest estimate of your age whenever applicable.  Please 
note that Before Surgery does NOT include swelling in the breast from treatment for 
cancer, but is trying to determine if you had lymphedema before developing breast cancer 
or having surgery.  Please answer the applicable questions if you are a relative of a woman 
with breast cancer. 
 
Do any of your family members have lymphedema?    Yes       No       Not Sure 
 
If yes, please list how they are related to you and the age at which they first developed lymphedema.   
Also note if the lymphedema is Primary (genetic or unknown) or Secondary (result of surgery, injury, 
etc.). 
 
Relationship to you:                          Age symptoms began: Cause of lymphedema: 
 
                                                                                                Primary      Secondary      Not Sure 
                                                                                                Primary      Secondary      Not Sure 
 
                                                                                                Primary      Secondary      Not Sure 
 
 
Do you have lymphedema?    Yes      No Longer      Never      Not Sure 
If yes ,age at the first sign of swelling: ______________________________ 
Has your lymphedema been diagnosed by a doctor or physical therapist?   Yes      No    
   
Did you ever have swelling or were you ever diagnosed with lymphedema BEFORE you developed breast cancer? 
  Yes       No       Not Sure;  If Yes, At what age did symptoms first begin?                           
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Age at Diagnosis:                            ;   Please describe your symptoms:       
             
 
Did you ever have swelling or were you ever diagnosed with lymphedema AFTER you developed breast cancer? 
  Post-Surgical Only     Yes       No       Not Sure If Yes:  
At what age did symptoms first begin?                                Age at Diagnosis:                                          ; 
Please describe your symptoms:                                                                                                                          
                                                                                                                                                                          ; 
How long after surgery did symptoms begin?     0-3 Months     3-12 Months     >1 Year     Not Sure; 
Did swelling disappear?     Yes      No      Not Sure; How long did it last?________________                                    
; 
Did swelling return?          Yes      No      Not Sure; How old were you?     
 
Have you ever had swelling of your arms, hands, or fingers? If Yes, at what age?   ______________                          
Did it develop: 
  before Surgery       0-3 Months after Surgery      >3 Months after Surgery        Never      Not Sure? 
 
Have you ever had swelling of your legs, feet, or toes ?       If Yes, at what age? ______________ 
Did it develop: 
  before Surgery       0-3 Months after Surgery      >3 Months after Surgery      Following an accident      
  unrelated to cancer or treatment   Never      Not Sure? 
 
Do you have a history of recurring skin infections or sores involving your arms, hands, fingers, legs, feet, or toes? 
(example: cellulitis, erysipelas) If so, age when this first occurred?                                              ;   
 
Did it develop: 
  before Surgery       0-3 Months after Surgery      >3 Months after Surgery      Following an accident      
  unrelated to cancer or treatment   Never      Not Sure 
 
Have you ever been hospitalized for an infection?  If Yes, at what age?                           ;   
 
Did it develop: 
  before Surgery       0-3 Months after Surgery      >3 Months after Surgery      Following an accident      
  unrelated to cancer or treatment   Never      Not Sure 
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III. If you answered Yes to any of the questions in Section II, please complete this section; 
       Otherwise, please skip to Section IV. 
 
Please indicate which areas of your body are, or were, affected by swelling (check all that apply): 
  Left Hand     Left Arm     Left leg     Neck     Chest      Buttocks 
  Right Hand    Right Arm    Right Leg      Face     Abdomen   Genitals 
  Left Foot         Right Foot 
Was the onset of your swelling:       Gradual (slow)       Rapid (acute)       Not Sure? 
Is there a specific event which you feel brought on your first episode of swelling?      Yes      No      Not Sure 
(examples: puberty, pregnancy, injury, infection, sunburn, insect bite, surgery, cancer, radiation therapy, long flight) 
If yes, what was it and how old were you?                    
 
 
Is your swelling, or has it ever been, painful?      Yes      No      Not Sure 
Please describe:                                                       
 
 
Have you ever had treatment for lymphedema?      Yes      No      Not Sure  
 
Please check all that apply: 
  CDP/MLD      Bandaging         Compression Garments        Pump 
  Surgery             Acupuncture      Herbs/Supplements:                                                 
  Other:                                                                                                                                                             
 
Please describe each treatment, the age(s) at which you had it, and if it was successful: 
a)               
b)               
c)                
 
Have you found any factors that increase or worsen your swelling?      Yes      No      Not Sure 
If Yes: a)               
b)                
Have you found any factors that decrease your swelling?         Yes      No      Not Sure 
If Yes: a)                
b)                
                                                                                                                                                                                           
 
IV. COMMENTS: Please use the space below to add any information, make comments, or ask any questions. 
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